Charles H. Paul Overview
The FDA's transition from the long-standing Quality System Regulation (QSR) to the new Quality Management System Regulation (QMSR) represents a major shift in how medical device manufacturers are expected to structure and demonstrate their quality systems. The QMSR aligns U.S. regulatory expectations with ISO 13485:2016, meaning compliance is no longer focused only on meeting procedural requirements, but on showing consistent, risk-based control of processes throughout the product lifecycle. This change reflects FDA's emphasis on global harmonization, stronger supplier oversight, and quality systems that can detect, prevent, and respond to risks proactively rather than reactively.
For manufacturers, this transition requires more than simply updating procedures-it involves reassessing how quality activities are linked, documented, governed, and communicated across the organization. Risk management must be embedded into daily decision-making, design control must clearly translate user needs into safe and effective products, and supplier quality systems must demonstrate real performance oversight, not just qualification paperwork. The shift also places greater weight on competency-based training, management accountability, and evidence that CAPAs and quality improvements are effective. When implemented correctly, the move to QMSR not only supports regulatory compliance but strengthens the organization's overall quality culture and operational maturity.
Why should you Attend
Organizations that manufacture medical devices must now adapt to a new regulatory framework that places greater emphasis on risk-based control, global alignment, and demonstrated quality system effectiveness. Attending this webinar will help you understand exactly what is changing as the FDA transitions from QSR to QMSR, how these expectations compare to ISO 13485, and what practical steps your organization should take to update procedures, training, supplier oversight, and documentation. You will learn how to perform an effective gap assessment, prioritize changes, and develop an implementation roadmap that strengthens compliance without disrupting operations. If your goal is to transition confidently, avoid rework, and reduce the risk of future inspection findings, this session will provide the clarity and direction you need.
Areas Covered in the Session
From QSR to QMSR: Practical Transition Strategies for Medical Device Manufacturers
Who Will Benefit
Charles H. Paul is the President of C. H. Paul Consulting, Inc. - a regulatory, manufacturing, training, and technical documentation consulting firm - celebrating its twentieth year in business in 2017. He has been a regulatory and management consultant and an Instructional Technologist for 30 years and has published numerous white papers on various regulatory and training subjects. The firm works with both domestic and international clients designing solutions for complex training and documentation issues.
He has held senior positions in consulting and in corporate training development prior to forming C. H. Paul Consulting, Inc. He also worked for several years in government contracting managing the development of significant Army-wide training development contracts impacting virtually all of the active Army and changing the training paradigm throughout the military.
He has dedicated his entire professional career explaining the benefits of performance-based training